Targeting PEDF deficiency‐induced neural impairment may provide a novel avenue for the development of new therapeutic applications for neurodegenerative diseases associated with glutamate‐induced excitotoxicity. This evidence concerns the gene SERPINF1 and neurodegenerative disease.